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In Brief
The relationship between onset of HIV
viremia and CD8+ T cell responses is not
well defined. Walker and colleagues
screened high-risk uninfected women to
identify cases of hyperacute infection,
and show that themagnitude and kinetics
of initial HIV-specific CD8+ T cell
responses are associated with
subsequent control of viremia.
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CD8+ T cells contribute to the control of HIV, but it is
not clear whether initial immune responses modulate
the viral set point. We screened high-risk uninfected
women twice a week for plasma HIV RNA and identi-
fied 12 hyperacute infections. Onset of viremia eli-
cited a massive HIV-specific CD8+ T cell response,
with limited bystander activation of non-HIV memory
CD8+ T cells. HIV-specific CD8+ T cells secreted little
interferon-g, underwent rapid apoptosis, and failed
to upregulate the interleukin-7 receptor, known to
be important for T cell survival. The rapidity to peak
CD8+ T cell activation and the absolute magnitude
of activation induced by the exponential rise in
viremia were inversely correlated with set point
viremia. These data indicate that rapid, high magni-
tude HIV-induced CD8+ T cell responses are crucial
for subsequent immune control of acute infection,
which has important implications for HIV vaccine
design.INTRODUCTION
Human and animal studies of acquired immune deficiency syn-
drome (AIDS) virus infections provide unequivocal evidence
that CD8+ T cells contribute to immune containment (reviewed
in Walker and McMichael, 2012). The HIV viral set point is the
stable viral load that is established after acute infection. In acute
HIV infection in humans, HIV-specific CD8+ T cell responses,
measured by interferon-g (IFN-g) secretion, appear as the viralImload is declining to the set point, suggesting that these cells
contribute to initial viral control (Borrow et al., 1994; Koup
et al., 1994). Moreover, depletion of CD8+ T cells in acute AIDS
virus infection in macaques leads to persistent high-magnitude
viremia, which declines as these cells reappear (Jin et al.,
1999; Schmitz et al., 1999). Viral evolution in response to HIV-
specific CD8+ T cell responses as the viral set point is reached
provides further evidence of early immune pressure (Goonetil-
leke et al., 2009; Liu et al., 2013). The viral set point following
acute HIV infection is predictive of subsequent disease progres-
sion (Lyles et al., 2000), suggesting that early responses play a
crucial role in the subsequent control of viremia, but whether
initial immune responses modulate the viral set point has not
been determined.
Studies of acute HIV infection have largely been conducted as
viral load is declining from the peak (Appay et al., 2002; Goone-
tilleke et al., 2009; Liu et al., 2013; Trautmann et al., 2012; Turn-
bull et al., 2009), and therefore little is known about the initial
phase of the CD8+ T cell response. Such studies have been chal-
lenging since hyperacute infection, defined here as the period
between onset of detectable plasma viremia and peak viral
load, remains poorly characterized due to the difficulty of identi-
fying infections prior to peak viremia. Pre-peak viral dynamics
have been measured in plasma blood donors, but the unavail-
ability of cells from that cohort has left questions regarding
corresponding T cell dynamics unanswered (Freel et al., 2010;
Ribeiro et al., 2010). T cell studies performed in the early stages
of acute HIV infection have shown that antiviral CD8+ T cell re-
sponses measured by IFN-g secretion are narrowly directed
and of low magnitude (Dalod et al., 1999; Radebe et al., 2011;
Streeck et al., 2009; Turnbull et al., 2009). This contrasts with
the high magnitude of CD8+ T cell activation that have been
noted during the period from peak viremia to viral set point in
HIV infection (Appay et al., 2002; Pantaleo et al., 1994), in excessmunity 43, 591–604, September 15, 2015 ª2015 Elsevier Inc. 591
of measurements of virus-specific immunity by IFN-g Enzyme-
Linked ImmunoSpot (ELISPOT). Early T cell activation has
been attributed to bystander activation induced by HIV (Bangs
et al., 2006; Doisne et al., 2004), but studies of TCR repertoire
showing oligoclonal expansions imply that they could be anti-
gen-specific (Pantaleo et al., 1994; Wilson et al., 1998). Indeed,
following yellow fever or vaccinia virus immunization, a massive
activation of virus-specific CD8+ T cells is induced, without
appreciable bystander activation (Miller et al., 2008). The rela-
tively weak antigen-specific CD8+ T cell responses reported in
early HIV infection seem inconsistent with the observed rapid
decline in plasma viral load (pVL), typically in excess of 10,000
fold. Likewise, although the magnitude of initial CD8+ T cell re-
sponses to a given epitope is associated with a more rapid
time to immune escape, relatively weak IFN-g ELISPOT re-
sponses are observed even for immunodominant epitopes at
the time of rapid viral load decline (Borrow et al., 1997; Brumme
et al., 2008; Goonetilleke et al., 2009; Liu et al., 2013; Radebe
et al., 2015).
In this study, we sought to define the onset, magnitude, and
evolution of CD8+ T cell responses and their relation to viral
load dynamics during the period from onset of HIV viremia to
pVL set point. We established a cohort of young HIV-negative
women at very high risk of HIV-1 clade C virus infection in
KwaZulu-Natal, South Africa, where the reported rate of HIV-
prevalence in those from 15 to 49 years of age is 27% (Delva
and Abdool Karim, 2014). This study, termed FRESH, for Fe-
males Rising through Education, Support and Health, had
two interlinked objectives. One was to establish a pathway
out of the socioeconomic constraints that put women at risk
of HIV infection (Kalichman et al., 2006), by provision of an
intensive empowerment, life skills, and job readiness curricu-
lum, coupled with HIV prevention education, through classes
taken twice a week over the course of a year. The second
objective was to cryopreserve baseline blood samples, screen
each participant twice a week by finger-prick plasma HIV RNA
testing for evidence of acute HIV infection, and examine the
relationship between onset of viremia and adaptive CD8+
T cell responses. Here we report results on the first 12 subjects
identified. Contrary to the notion that early T cell responses are
low in magnitude, our results indicate that acute HIV infection
elicits a massive HIV-specific CD8+ T cell response, with
limited bystander activation of memory CD8+ T cell responses
to other pathogens. These expanded cells then undergo rapid
apoptosis and lack phenotypic markers associated with long-
term memory development. Importantly, the data show that
the magnitude and rapidity of induction of activated CD8+
T cells are crucial factors in modulating subsequent immune
control.
RESULTS
Analysis of 12 Subjects with Hyperacute HIV Infection
Demonstrates Exponential Rise in Viremia Coincident
with CD4+ T Cell Decline
Finger prick blood samples were obtained from high-risk unin-
fected women twice a week for quantitative HIV RNA testing.
Twelve subjects were identified with hyperacute infection, de-
fined by detection of HIV RNA prior to peak viremia, representing592 Immunity 43, 591–604, September 15, 2015 ª2015 Elsevier Inc.an incidence of 7.3 (95%CI = 3.8–12.8) per 100 person-years. Of
the 11 subjects for whom we could test the earliest sample, all
were in Fiebig Stage I (Fiebig et al., 2003). The time from enroll-
ment in the study to the first detection of viremia ranged from 39
to 284 days. pVL measurements from each of the 12 infected
subjects were obtained at 3–6 time points during the rise to
peak viremia (Figure 1). The median pVL at first detection was
3.2 log10 (IQR 2.66–4.57) HIV RNA copies/ml. The median peak
pVL was 7.01 log10 (IQR 6.68–7.66) RNA copies/ml, more than
10-fold higher than the median peak pVL of 5.80 log10 observed
in plasma donors infectedwith clade B virus (Ribeiro et al., 2010).
Despite differences in peak pVL compared to plasma donors,
the calculated median viral doubling time was 16.4 hr corre-
sponding to 0.68 days (IQR 0.65–0.78 days) (Table S1), which
is comparable to a median doubling time of 0.65 days in plasma
donors from a clade B endemic region (Ribeiro et al., 2010). R0,
the basic reproductive number that defines the number of in-
fected cells a single cell gives rise to when target cells are not
limiting, ranged from 5.5 to 14.9 (Table S1). Frequent measure-
ment of peripheral blood CD4 cell counts revealed a rapid
decline in cell numbers coincident with peak viremia, reaching
a nadir that was on average 37% of the documented pre-infec-
tion average value. CD4 cell counts rebounded but always to
numbers below pre-infection numbers as the viral load set point
was achieved (Figure 1). These data demonstrate the feasibility
of identifying hyperacute HIV infection, and document the expo-
nential rise in acute viremia coincident with the rapid decline in
CD4+ T cell counts.
The Rapidity and Magnitude of CD8+ T Cell Activation
Correlate with Set Point Viremia
To elucidate the nature of the CD8+ T cell response induced
following onset of plasma viremia, we analyzed the expression
patterns of CD38 and HLA-DR, markers that have been used
to define T cell activation during the acute phase of viral infec-
tions and following vaccination (Appay et al., 2002; Doisne
et al., 2004; Miller et al., 2008). Both markers had low pre-infec-
tion cell surface expression, allowing for the unequivocal identi-
fication of an emerging activated CD8+ T cell population induced
by acute HIV infection. Within 1 to 3 days following onset of
plasma viremia, (DFOPV), and prior to peak viremia, CD8+
T cell activation was already detectable, ultimately increasing
from less than 1% pre-infection to a peak as high as 77% (IQR
41.8%–67.4%) of total CD8+ T cells (Figures 2A and 2B). Peak
activation was delayed compared to peak viremia by a median
of 2 weeks, reaching maximal values approximately 3 weeks af-
ter first detection of viremia (Figure 2C), and then contracting in
all 11 participants evaluated, reaching a quasi-steady state at a
median of 80 days (IQR 73–107) (Figure 2B).
The observed differences in the kinetics of peak activation of
CD8+ T cells prompted us to determine whether the rapidity
and magnitude of CD8+ T cell activation correlated with set point
viremia, a known predictor of subsequent disease progression
(Lyles et al., 2000). As shown in Figure 2D, greater time to
peak activation positively correlated with higher pVL set point
(Spearman r = 0.7, p = < 0.03). In contrast, the frequency of acti-
vated (CD38+HLA-DR+) CD8+ T cells at peak activation inversely
correlated with HIV viral set point (Spearman r =0.8, p = 0.009)
(Figure 2E). Although CD4 count is a strong predictor of disease
Figure 1. Dynamics of Absolute CD4 Counts and Plasma Viral Loads during Hyperacute HIV Infection
Plasma HIV-1 RNA magnitude (red) and absolute CD4 counts (blue) before HIV infection and following onset of detectable plasma viremia in 12 subjects with
hyperacute HIV infection that were not receiving antiretroviral treatment. See also Table S1.progression in chronic HIV infection (Phillips and Lundgren,
2006), nadir CD4 counts did not correlate with set point pVL
(data not shown, Spearman r = 0.15, p = 0.65). Because pVL
set point predicts subsequent HIV disease progression (Lyles
et al., 2000), these data show that the kinetics and magnitude
of HIV-induced CD8+ T cell activation in hyperacute infection
impact subsequent immune control of HIV.
The ability of HIV-specific CD8+ T cells to proliferate is strongly
correlated with viral control in chronic infection (reviewed in Mi-
gueles and Connors, 2015). To further define the expansion and
subsequent contraction of CD8+ T cells in hyperacute infection,Imwe measured intracellular markers associated with cellular pro-
liferation and cell survival. Ki67 is upregulated in cells undergoing
division due to recent antigen stimulation (Gerdes et al., 1984;
Hazenberg et al., 2000), whereas the anti-apoptotic protein
Bcl-2 is downregulated in effector cells (Grayson et al., 2000).
Pre-infection CD8+ T cells from the 11 donors evaluated had
a resting phenotype that was Ki67negBcl-2high, with only a me-
dian of 0.4% (IQR 0.1%–0.8%) displaying a cycling phenotype
(Ki67high Bcl-2low) (Figure 3A). Upon HIV infection a population
of Ki67highBcl-2lowCD8+ T cells rapidly emerged, reaching
a median of 25.4% (IQR 13.5%–33.5%) (Figure 3B). Peakmunity 43, 591–604, September 15, 2015 ª2015 Elsevier Inc. 593
Figure 2. CD8+ T Cell Activation following Onset of Plasma Viremia
Longitudinal analysis of CD38 and HLA-DR expression on CD8+ cells after HIV infection.
(A) Representative FACS plots gated on CD8+ cells expressing CD38 and HLA-DR. Days following onset of plasma viremia (DFOPV) are indicated.
(B) Longitudinal dynamics of activated (CD38+HLA-DR+) CD8+ cells for 11 donors in whom samples were available for analysis.
(C) Representative relationship between HIV-induced CD8+ cell activation kinetics and contemporaneous viral load.
(D) Correlation between time to peak activation and viral load setpoint.
(E) Correlation between frequency of activated CD8+ cells at peak activation and viral load set point. Spearman’s rank correlation was used in (D) and (E).expression of these markers was delayed by approximately one
week compared to peak viremia (representative example, Fig-
ure 3C). Simultaneous analysis of the expression pattern for
the four markers evaluated (CD38, HLA-DR, Ki67, and Bcl-2)
on CD8+ T cells confirmed that Ki67high and Bcl-2low population
was a subset of the CD38, HLA-DR double-positive population594 Immunity 43, 591–604, September 15, 2015 ª2015 Elsevier Inc.(Figure 3D). We observed a negative relationship between the
frequency of Ki67high Bcl2low CD8+ T cells and pVL set point
(Spearman r = 0.7, p = 0.03) (Figure 3E). These data indicate
that the activated cells are also undergoing vigorous proliferation
and that CD8+ T cell proliferation induced by acute HIV infection
is associated with subsequent viral control.
Figure 3. CD8+ T Cell Proliferation and Apoptosis following Onset of Viremia
(A) Representative FACS plots gated on CD8+ cells expressing Ki-67 and Bcl-2.
(B) Summary data for the longitudinal analysis of proliferating and pro-apoptotic CD8+ cells for 11 donors evaluated.
(C) Representative relationship between Ki67negBcl-2lowCD8+ T cells and contemporaneous viral load.
(D) CD8+T cell co-expression of CD38, HLA-DR, Ki67, and Bcl-2.
(E) Correlation between peak Ki67negBcl-2lowCD8+ T cells and viral load set point. Spearman’s rank correlation was used in (E).Hyperacute Activated CD8+ T Cells Are HIV Specific
The observed correlation between the kinetics of activated CD8+
T cells and pVL set point suggested that these cells might be
HIV-specific. HIV-specific CD8+ T cell responses were detect-
able by intracellular cytokine staining (ICS) for IFN-g production
as early as 3 days after detection of viremia in some subjectsIm(Figure S1A), but were weak at peak activation, and appeared
to increase as activation was decreasing (Figure S1B). Using
IFN-g ELISPOT to determine responses to the entire proteome,
we found that five of nine donors tested had a detectable HIV-
specific CD8+ T cell response by day 7–10 following the onset
of plasma viremia, when CD8+ T cell activation was peakingmunity 43, 591–604, September 15, 2015 ª2015 Elsevier Inc. 595
Figure 4. Hyperacute HIV Infection Induces Strong CD8+ T Cell Responses with Degranulation Potential
HIV-specific CD8+ T cell responses weremeasured by ICS after overnight incubation with autologous HIV-infected CD4+ cells. Uninfected autologous CD4+ cells
co-cultured with CD8+ cells were used as a negative control.
(A) Representative flow plots demonstrating CD107a expression on CD8+ cells.
(B) Upper panel shows CD107a expression on ex vivo CD8+ cells from 14 DFOPV incubated for 12 hr with HIV infected autologous CD4+ T cells. The lower panel
shows CD107a expression on CD8+ cells from 14 DFOPV incubated in IL-2 containing media for 5 days prior to co-culture with infected autologous CD4+ T cells.
(C) Proportion of CD8+ cells secreting cytokines following stimulation with HIV infected autologous CD4+ cells. Background responses in the uninfected co-
culture condition are subtracted. Statistical significance was determined using Mann-Whitney and Kruskal Wallis tests. Error bars represent mean ± SEM.
(D) Comparison between proliferating CD8+ T cells and CD107a-positive cells at peak activation time points (also see supplemental figures). Statistical signif-
icance was determined using Mann-Whitney test. Error bars represent mean ± SEM. See also Figures S1, S2, and S3.(Figure S1C)withmany of the early responses targeting Gag, Pol,
and Nef (Figure S1D). Longitudinal analysis revealed the tran-
sient nature of many of the early responses given that a median
of 31% (IQR 11% to 52%) of the early responses measurable in
the first 30 DFOPV became undetectable at later time points,
when new responses were arising (Figure S2).
The above studies measured the ability of CD8+ T cells to pro-
duce cytokines in response to synthetic HIV peptides, but did not596 Immunity 43, 591–604, September 15, 2015 ª2015 Elsevier Inc.measure the recognition of endogenously processed epitopes.
To address this, we infected autologous expanded CD4+
T cells with a patient-derived clade C HIV virus and used to stim-
ulate peripheral blood mononuclear cells (PBMCs). Representa-
tive data from one subject (Figure 4A) show that nearly 20% of
total CD8+ T cells at the time of peak activation mobilized
CD107a upon exposure to HIV infected cells, compared to a
background of 2.9% cells in a pre-infection sample. Incubation
of CD8+ T cells in interleukin-2 (IL-2) supplemented media for
5 days resulted in an average 30-fold increase in antigen-specific
IFN-g production (Figure 4B) despite negligible ex vivo prolifera-
tion during the incubation period (Figure S3). Summary data for
six donors using CD8+ T cells rested in IL-2-supplemented me-
dia showed significantly greater CD107a expression compared
to IFN-g, TNF-a, and IL-2 responses (Kruskal–Wallis p <
0.0001) (Figure 4C). Importantly, CD107a expression at peak
activation was not significantly different from the median fre-
quency of in vivo proliferating cells defined by Ki67high, Bcl-2low
(p = 0.6) (Figure 4D). These results suggest that the majority of
proliferating CD8+ T cells were HIV-specific effector cells with
degranulation potential.
To further define the specificity of activated CD8+ T cells, we
used HLA class I tetramers to directly stain antigen-specific
cells. Despite the limited availability of tetramers, individual re-
sponses of 10% or greater were detected in three of four sub-
jects evaluated. In subject 208, for whom the most tetramers
(five) were available, 36% of all CD8+ T cells were HIV-specific,
at a timewhen 51%of all CD8+ T cells were activated (Figure 5A).
Similarly, three tetramers identified 34% of total CD8+ T cells as
HIV-specific in a second subject at a time when 50% of CD8+
T cells were activated (Figure 5B). In a third donor, only two
HLA-matched tetramers were available, but these identified
12% of total CD8+ cells as HIV-specific for a sample with 66%
activated CD8+ T cells (Figure 5C). The fourth donor did not
have detectable responses to four HIV tetramers tested, but
HIV-specific CD8+ T cell responses were clearly present, as evi-
denced by weak IFN-g ELISPOT responses (donor 309 in Fig-
ure S1 and S2), suggesting that the tetramers used did notmatch
in vivo epitopes.
The tetramer data indicated much higher frequencies of HIV-
specific CD8+ T cells than did the IFN-g ELISPOT assay. Dual
staining by tetramer and IFN-g at peak activation revealed that
on average only 20% of tetramer+ cells produced measurable
amounts of IFN-g, whereas comparative analysis showed that
CMV tetramer+ cells secreted significantly more IFN-g (p =
0.01) (Figures 5D and 5E). Given that only a fraction of known
epitopes were tested, and that over half of the epitopes targeted
in acute HIV infection have not been previously identified (Liu
et al., 2013), these data strongly support the hypothesis that
the majority of expanded CD8+ T cells observed during the hy-
peracute phase of the infection are HIV-specific.
Limited CD8+ T Cell Bystander Activation during Acute
HIV Infection
Having confirmed that a major fraction of activated proliferating
cells were HIV-specific by tetramer staining, we next investi-
gated whether CD8+ T cell bystander activation might account
for some of the additional CD8+ T cell activation. Comparative
analyses focused on cytomegalovirus (CMV)-, influenza-, and
Epstein-Barr virus (EBV)-specific CD8+ T cells in four of the
acutely infected subjects. For donor 093, 62.6% of HIV-specific
tetramer+ cells were activated at peak activation, whereas only
25.7% of CMV-specific and 3.1% of influenza-specific tetramer+
cells were activated (Figure 6A). Similarly, in donor 102, 76.5%of
HIV-specific cells displayed an activated phenotype, with mini-
mal activation of CMV- and EBV-specific CD8+ T cell responses
(Figure 6B). Higher magnitude activation was observed for a totalImof 13 different HIV-specific tetramers tested in four study partic-
ipants compared to five CMV-, three influenza-, and three EBV-
specific responses (Kruskal-Wallis p = 0.001) (Figure 6C).
Together, these data suggest that there was minimal contribu-
tion of bystander activation to the observed HIV-induced CD8+
T cell expansion.
Marked Apoptosis of HIV-Specific CD8+ T Cells in
Hyperacute Infection
Our data indicate that themajority of the activatedCD8+ T cells in
hyperacute infection are HIV-specific, and that some of the
earliest antigen-specific responses do not persist. We next
investigated whether the early massive activation accelerated
cell death given that apoptosis is intimately linked with short-
lived effector cells in the acute phase of a viral infection (Badovi-
nac et al., 2002). Consistent with the observed decrease in Bcl-2
expression in activated and proliferating CD8+ T cells (Figures 7A
and 7B), activated cells also expressed high magnitude of CD95
expression, a potent inducer of apoptosis and one of the major
effector mechanisms of activated CD8+ T cells involved in cell
killing (Figure 7A) (Ka¨gi et al., 1994). Additionally, the activated
CD8+ T cells failed to upregulate CD127 (Figure 7C), which is
important for cell survival during the contraction phase of an
acute immune response (Kaech et al., 2003; MacPherson
et al., 2001). Dual annexin V and propidium iodide (PI) staining re-
vealed that CD8+ T cells from peak activation failed to survive
overnight incubation compared to pre-infection (p = 0.02) and
post CD8+ T cell activation (p = 0.03) samples (Figure 7D). No
survival defect was observed for CD4+ T cells (Figure 7E).
Tetramer immunophenotyping confirmed that HIV-specific cells
were selectively more susceptible to apoptosis compared to
bystander CD8+ T cell responses (Figure 7F). Combined, these
data show that newly differentiated effector CD8+ T cells under-
went significant contraction despite ongoing viremia, consistent
with activation induced cell death and failure to upregulate the
CD127 molecule involved in long-term CD8+ T cell memory
formation.
DISCUSSION
The relationship between the onset of HIV viremia, adaptive im-
mune responses, and subsequent viral control has not been well
defined, due to difficulty obtaining samples prior to and at peak
viremia. Here we identified HIV infected subjects at the onset of
plasma viremia by screening high-risk uninfected women in an
area of extremely high incidence of infection twice a week. Our
results indicated that hyperacute HIV infection defined as the
period between first detectable and peak plasma viremia, eli-
cited vigorous activation and proliferation of CD8+ T cells, with
up to 77% of peripheral CD8+ T cells expressing HLA-DR and
CD38. We determined that the majority of these early-activated
cells were HIV-specific, as inferred by their ability to degranulate
when stimulated with autologous HIV-infected CD4+ T cells, by
HLA class I tetramer staining, and by lack of appreciable
bystander activation. Moreover, we showed that this initial
robust CD8+ T cell response impacted viral control, consistent
with what has been observed in SIV rhesus macaque immuniza-
tion models (Hansen et al., 2011; Hel et al., 2002). Overall, these
data indicated that the onset of plasma HIV viremia is markedlymunity 43, 591–604, September 15, 2015 ª2015 Elsevier Inc. 597
(legend on next page)
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immunogenic for HIV-specific CD8+ T cell responses that control
acute viremia and that traditional measures of IFN-g production
are an inadequate measure of these responses in the acute
phase of infection.
A unique aspect of this study was the availability of samples
from the time of onset of viremia, allowing accurate definition
of kinetics and magnitude of CD8+ T cell activation. Both the
promptness of induction and the peak magnitude of activated
CD8+ T cells impacted the rate of early virus replication, indi-
cating that these responses have direct antiviral function. The
ability of these cells to proliferate also impacted pVL set point,
indicating that the ability to proliferate is critical in acute infection,
as has been shown in chronic infection (Migueles et al., 2002;
Ndhlovu et al., 2013). However, increased apoptosis and lack
of CD127 expression were observed on the activated CD8+
T cells, indicating that impaired long-term memory might
contribute to the inability to fully suppress the virus despite
robust induction of HIV-specific CD8+ T cells elicited by onset
of viremia, an important focus for future studies. In addition,
persistent antigenic exposure might affect resolution of CD8+
T cell activation resulting in impaired CD8+ T cell function and
faster HIV disease progression (Cossarizza et al., 2012; Traut-
mann et al., 2012).
Previous studies of CD8+ T cell responses measured by IFN-g
secretion to HIV peptide antigens in acute infection have largely
focused on the period following peak viremia (Appay et al., 2002;
Goonetilleke et al., 2009; Liu et al., 2013; Radebe et al., 2015;
Trautmann et al., 2012; Turnbull et al., 2009). Those studies sug-
gested that the initial CD8+ T cell response is weak, asmeasured
by ICS or ELISPOT. Here, availability of pre-infection samples
and twice weekly sampling allowed us to more precisely define
the onset of viremia and the evolution of CD8+ T cell responses.
By IFN-g staining we found that responses were weak during
peak activation, and increased once activation returned to base-
line. In contrast, the early HIV-specific CD8+ T response was
robust by tetramer staining. In one subject for whom five different
tetramers were available, 36% of all CD8+ T cells were HIV spe-
cific. Because responses to many additional potential HIV epi-
topes could not be tested due to lack of additional epitopes for
the class I tetramers used, and lack of any tetramers for four of
the subject’s class I alleles, these data likely underestimated
the magnitude of HIV-specific responses. The use of tetramers
also enabled us to determine that acute infection was associated
with impaired IFN-g production, but this increased following the
return of CD8+ T cell activation to baseline, consistent with earlier
studies (Radebe et al., 2011; Streeck et al., 2014; Trautmann
et al., 2012). It is conceivable that the aforementioned limitations
of IFN-g as readout contributed to the lack of association be-
tween breadth or magnitude and viral load set point reported
in recent acute infection studies (Radebe et al., 2011; Streeck
et al., 2014). Our data show that the use of autologous infectedFigure 5. Analysis of HIV-Specific CD8+ T Cell Responses during Hype
(A–C) PBMCs were stained with MHC class I tetramers specific for HIV and anti
panels show frequencies of HIV-specific CD8+ T cells for each HIV tetramer teste
HLA-DR overlaid on total CD8+ T cells (red dots). Data for subjects 208, 079, an
(D) Flow plots show combined tetramer staining and cytokine secretion measure
(E) Proportion of HIV-specific and CMV-specific tetramer+ cells secreting IFN-g
significance was determined using Mann-Whitney test. Error bars represent mea
Imcells as targets and the use of tetramers allowed for a more sen-
sitive estimation of virus-specific CD8+ T cell responses during
the early phase of the infection. Previous studies in chronic infec-
tion show that the majority of in vivo primed, circulating HIV-spe-
cific CD8+ T cells are discordant for cytolysis and cytokine secre-
tion, notably IFN-g (Kostense et al., 2002; Varadarajan et al.,
2011). Defining the mechanism accounting for the impaired
IFN-g production during acute infection will be an important
objective of future studies.
In contrast to the robust activation of HIV-specific CD8+
T cells, CD8+ T cells specific for pathogens such as CMV,
EBV, and influenza virus were minimally activated even when a
very high proportion of total CD8+ T cells displayed an activated
phenotype. These data suggested that very limited bystander
activation was occurring during the acute phase of HIV infection,
consistent with previous reports in other acute viral infections
and following immunization (Butz and Bevan, 1998; Miller
et al., 2008; Murali-Krishna et al., 1998). The modest activation
of CMV- and EBV-specific responses, which tend to reactivate
during acute viral infections, further supports the notion that
most of the observed activation is antigen-driven rather than
cytokine-driven bystander activation.
These studies also provide insight into the fate of the earliest
CD8+ T cell responses in acute infection. Activated HIV-specific
CD8+ T cells expressedCD95, a death receptor that leads to pro-
grammed cell death, and downregulated the pro-apoptotic pro-
tein Bcl-2, underscoring their susceptibility to activation-induced
cell death. Additionally, even in this very early stage of infection
HIV-specific CD8+ T cell responses did not upregulate the IL-7
receptor, which promotes long-term survival (Kaech et al.,
2003). These data confirm previous reports in humans and SIV
models showing a survival defect and the skewed phenotype
with a preponderance of pro-apoptotic effector CD8+ T cells in
the first few weeks of infection (Mueller et al., 2007; Trautmann
et al., 2012). Spontaneous cell death coupled with the pro-
apoptotic phenotype exhibited by early responses suggests
that premature cell death might be one reason for lack of persis-
tence of early responses and consequently incomplete virus
suppression. Although immune escape has also been shown
to lead to decreases in HIV-specific CD8+ T cell responses (Liu
et al., 2013), this is likely to occur over a more protracted time
course and be different for different epitopes, suggesting that
apoptosis is the major driver of the uniform decline in activated
CD8+ T cells observed here.
In conclusion, these results show that longitudinal sampling of
high-risk uninfected persons can identify cases of hyperacute
infection, allowing for the assessment of the earliest interactions
between virus and host. Our data indicate that onset of HIV
viremia induces vigorous CD8+ T cell activation and proliferation,
the majority of which is HIV specific but would be missed
by traditional IFN-g ELISPOT assays. The more rapidly peakracute HIV Infection using MHC Class I Tetramers
bodies against CD38 and HLA-DR. All plots are gated on CD8+ T cells. Upper
d. Blue dots depict the frequency of tetramer+ cells co-expressing CD38 and
d 093 are shown in (A), (B), and (C), respectively.
d by ICS. Representative data for one of the four donors tested are shown.
following optimal peptide stimulation of a peak activation sample. Statistical
n ± SEM.
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Figure 6. Assessment of Bystander CD8+ T Cell Activation during Hyperacute HIV Infection
(A and B) Intra-donor activation (CD8+ CD38+ HLA-DR+ cells) profiles of HIV, CMV, EBV, and influenza-virus-specific (tetramer+) CD8+ T cells. Data for two donors
with detectable tetramer+ cells specific for three different pathogens are shown in (A) and (B). The first columns show flow plots gated on tetramer+ cells, the
second column shows flow plots gated on tetramer+ cells that are double positive for CD38 and HLA-DR (blue dots) overlaid on total CD8+ T cells (red dots).
(C) Activation data for 13 HIV, 5 CMV, 3 EBV, and 3 influenza specific tetramer+ cells are graphed. Statistical significance was determined using Kruskal-Wallis
test. Error bars represent mean ± SEM.activation is achieved, and the greater the peak activation at-
tained, the lower the subsequent viral load set point. These
data thus indicate that rapid, high magnitude HIV-induced600 Immunity 43, 591–604, September 15, 2015 ª2015 Elsevier Inc.CD8+ T cell responses are critical for subsequent immune con-
trol of acute infection, and thus have important implications for
HIV vaccines.
Figure 7. Activation Profiles of CD8+ T Cells in Hyperacute HIV Infection
(A) Phenotypic analysis of HIV specific tetramer+ CD8+ cells.
The first flow plot is gated on tetramer+ cells, the second, third, and fourth plots depict tetramer+ cells (blue dots) overlaid on total CD8+ cells. (B and C) Data
showing frequencies of tetramer+ cells that are (B) Ki67high, BCL2low, and (C) CD127high are graphed. Statistical significance was determined usingMann-Whitney
and Kruskal-Wallis tests. Error bars represent mean ± SEM.
(legend continued on next page)
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EXPERIMENTAL PROCEDURES
Study Population and Blood Samples
Subjects were 18–23 year old HIV-negative women at very high risk of HIV-
1 clade C infection in Durban, South Africa. Blood and female reproductive
tract (FRT) samples were obtained at pre-infection, and participants at-
tended twice-weekly sessions in which a comprehensive empowerment,
life skills, and HIV prevention curriculum was provided by trained coun-
selors. At each twice-weekly visit, finger prick monitoring for plasma HIV
RNA was performed, with results provided within 24 hr. Upon detection
of viremia by NucliSens EasyQ v2.0 assay, participants were contacted,
health counseling provided, and additional blood samples collected. For
each donor, a pre-infection sample and serial post-infection samples
were obtained. Studies of the FRT are reported elsewhere (Anahtar et al.,
2015). All the participants provided written informed consent for and the
Biomedical Research Ethics Committee (BREC) of the University of Kwa-
Zulu-Natal and the institutional review board of Massachusetts General
Hospital approved the study.
Viruses and Synthetic Viral Peptides
Primary HIV clade C virus was prepared according to a previously described
protocol (Ndung’u et al., 2006). 410 overlapping 18-mer consensus clade C
peptide sequences spanning the entire expressed HIV proteome and optimal
class I restricted epitopes (http://hiv-web.lanl.gov) were synthesized at the
MGH Peptide Core Facility on an automated peptide synthesizer using F-
moc technology.
Flow Cytometry Analysis of T Cell Activation and Proliferation
Fresh or previously frozen PBMCs were first stained with viability dye for
10 min, washed, and surface stained at room temperature for 20 min. Cells
were permeabilized and fixed with intracellular staining reagents according
to the manufacturer’s instructions (BD Bioscience) before intracellular staining
with antibodies to Bcl-2 and Ki-67. Samples were then washed before acqui-
sition and analysis on a BD LSRFortessa flow cytometer (BD Biosciences).
Data analysis was performed using FlowJo software (Treestar).
ELISPOT and ICS Staining
ELSPOT assays were performed as described in a matrix system allowing
for identification of targeted peptides (Kiepiela et al., 2007). Responses
were regarded as positive if they had at least 3 times the mean number
of SFC in the three negative control wells; positive responses also had be
at least 50 SFC/106 PBMCs. For ICS, cells were first stimulated overnight
with HIV peptides and stained according to the BD Bioscience ICS proto-
col. ‘‘Fluorescence minus one’’ (FMO) staining was used to define the cutoff
for positivity.
Tetramer/ICS Studies
Stimulated PBMCs were stained with HLA class I-peptide tetrameric com-
plexes for 45 min at room temperature, washed in PBS, 0.5 mM EDTA, and
1% BSA, and surface stained with appropriate surface antibodies for 15 min
at room temperature in the dark. Cells were then permeabilized, fixed, and
intracellularly stained with IFN-g, IL-2, and TNF-a and analyzed on a BD
LSRFortessa flow cytometer.
Generation of CD4+ T Cell Targets and CD8+ Effector T Cells
CD4+ T cells were enriched by depleting CD8+ T cells using CD8+ microbe-
ads (Miltenyi Biotech) and rested for 4 hr. CD4+ T cells were stimulated
with 5 mg/ml of CD3+/CD8+ bi-specific antibody (Chen et al., 2012) in R10/
50 for 72 hr before infection with patient isolated clade C viruses for 48 hr.
Infection was monitored by flow cytometry after surface staining with CD4(D) Frequencies of dead CD8+ T cells (annexin-V+, PI+ CD8+ cells). Statistical
mean ± SEM.
(E) Frequencies of dead CD4+ T cells (annexin-V+, PI+ CD4+ cells) after overnight i
test. Error bars represent mean ± SEM.
(F) Flow cytometric data for two donors showing ex vivo expression of annexin V
602 Immunity 43, 591–604, September 15, 2015 ª2015 Elsevier Inc.antibody and intracellular staining for HIV-Gag (Kc57-FITC, Beckman
Coulter). CD8+ T cells were kept in R10/50 for 5 days prior to the co-culture
experiment.
HIV Infected Cell Recognition Assay
Freshly isolated or cultured CD8+ T cells were co-cultured with infected or
uninfected (mock) autologous CD4 T target cells at a 1:1 ratio. Anti CD107a
antibody (BD Bioscience) and the secretion inhibitor monensin used according
to the manufacturer’s instructions were added at the beginning of the 12-hr
stimulation. After overnight incubation, cells were surface stained fixed, per-
meabilized, and intracellularly stained with IFN-g, TNF-a, and IL-2 monoclonal
antibodies. Cells were analyzed by flow cytometry and data analysis was per-
formed using FlowJo software.
Statistical Analyses
Descriptive statistics, Kruskal Wallis tests, Spearman rank-correlation, and
Mann-Whitney tests were performed using GraphPad Prism version 5.0b. All
tests were two-tailed and p values of p < 0.05 were considered significant.
Estimates of rates of viral expansion, viral decline following peak viremia and
initial rate of CD4 decline were obtained by fitting linear mixed-effects models
on acute phase data as described before (Ribeiro et al., 2010). The fitting was
performed using the Statistical Analysis Toolbox in Matlab (Version R2014a).
Viral load set point was defined as average viral loads measured between
2 to 8 months following onset of plasma viremia because this is the interval
when viral loads for all are study participants reached steady state (Huang
et al., 2012).
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and one tables and can be
found with this article online at http://dx.doi.org/10.1016/j.immuni.2015.08.012.
AUTHOR CONTRIBUTIONS
Z.M.N. was responsible for the overall conduct of the study under the super-
vision of B.D.W.; Z.M.N., T.N., and B.D.W. contributed to the experimental
design. Z.M.N. and P.K. did the experiments and Z.M.N. analyzed the data.
K.D., T.N., and B.D.W. provided clinical samples. T.N. performed virus isola-
tion and titration. S.B., A.M., P.J.R.G., H.N.K., and A.L. provided tetramers
and technical expertise. M.G., K.S., and A.C. performed data and computa-
tional analyses. Z.M.N. and H.N.K. did the tetramer staining experiments.
Z.M.N. and B.D.W. wrote the paper, and all co-authors contributed to the
revisions.
ACKNOWLEDGMENTS
We would like to thank the FRESH participants, as well as the FRESH and
HIV Pathogenesis Programme (HPP) laboratory staff. This work was supported
by the Bill and Melinda Gates Foundation and the Collaboration for AIDS
Vaccine Discovery, the Witten Family Foundation, Dan and Marjorie Sullivan,
the Mark and Lisa Schwartz Foundation, Ursula Brunner, Gary and Loren Co-
hen, the International AIDS Vaccine Initiative (IAVI) (UKZNRSA1001), the NIAID
(R37AI067073), and an NIH funded Center for AIDS Research (P30 AI060354),
which is supported by the following NIH Co-Funding and Participating Insti-
tutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC, and
OAR, and the Howard Hughes Medical Institute. Additional funding was
received from the South African Research Chairs Initiative. We would like to
thank Drs. Alan S. Perelson and Ruy M. Rubeiro for their expert advice on viral
growth kinetics calculations, and Dr. Daniel E. Kaufmann, MD for critical
reading of the manuscript.significance was determined using Mann-Whitney test. Error bars represent
ncubation in R10. Statistical significance was determined using Mann-Whitney
by HIV tetramer+ and CMV tetramer+ cells at peak activation.
Received: February 20, 2015
Revised: June 2, 2015
Accepted: June 26, 2015
Published: September 8, 2015
REFERENCES
Anahtar, M.N., Byrne, E.H., Doherty, K.E., Bowman, B.A., Yamamoto, H.S.,
Soumillon, M., Padavattan, N., Ismail, N., Moodley, A., Sabatini, M.E., et al.
(2015). Cervicovaginal bacteria are a major modulator of host inflammatory re-
sponses in the female genital tract. Immunity 42, 965–976.
Appay, V., Papagno, L., Spina, C.A., Hansasuta, P., King, A., Jones, L., Ogg,
G.S., Little, S., McMichael, A.J., Richman, D.D., and Rowland-Jones, S.L.
(2002). Dynamics of T cell responses in HIV infection. J. Immunol. 168,
3660–3666.
Badovinac, V.P., Porter, B.B., and Harty, J.T. (2002). Programmed contraction
of CD8(+) T cells after infection. Nat. Immunol. 3, 619–626.
Bangs, S.C., McMichael, A.J., and Xu, X.N. (2006). Bystander T cell activation–
implications for HIV infection and other diseases. Trends Immunol. 27,
518–524.
Borrow, P., Lewicki, H., Hahn, B.H., Shaw, G.M., and Oldstone, M.B. (1994).
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control
of viremia in primary human immunodeficiency virus type 1 infection. J. Virol.
68, 6103–6110.
Borrow, P., Lewicki, H., Wei, X., Horwitz, M.S., Peffer, N., Meyers, H., Nelson,
J.A., Gairin, J.E., Hahn, B.H., Oldstone, M.B., and Shaw, G.M. (1997). Antiviral
pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during pri-
mary infection demonstrated by rapid selection of CTL escape virus. Nat. Med.
3, 205–211.
Brumme, Z.L., Brumme, C.J., Carlson, J., Streeck, H., John, M., Eichbaum, Q.,
Block, B.L., Baker, B., Kadie, C., Markowitz, M., et al. (2008). Marked epitope-
and allele-specific differences in rates of mutation in human immunodeficiency
type 1 (HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/
early HIV-1 infection. J. Virol. 82, 9216–9227.
Butz, E.A., and Bevan, M.J. (1998). Massive expansion of antigen-specific
CD8+ T cells during an acute virus infection. Immunity 8, 167–175.
Chen, H., Ndhlovu, Z.M., Liu, D., Porter, L.C., Fang, J.W., Darko, S.,
Brockman, M.A., Miura, T., Brumme, Z.L., Schneidewind, A., et al. (2012).
TCR clonotypes modulate the protective effect of HLA class I molecules in
HIV-1 infection. Nat. Immunol. 13, 691–700.
Cossarizza, A., Bertoncelli, L., Nemes, E., Lugli, E., Pinti, M., Nasi, M., De Biasi,
S., Gibellini, L., Montagna, J.P., Vecchia, M., et al. (2012). T cell activation but
not polyfunctionality after primary HIV infection predicts control of viral load
and length of the time without therapy. PLoS ONE 7, e50728.
Dalod, M., Dupuis, M., Deschemin, J.C., Goujard, C., Deveau, C., Meyer, L.,
Ngo, N., Rouzioux, C., Guillet, J.G., Delfraissy, J.F., et al. (1999). Weak anti-
HIV CD8(+) T-cell effector activity in HIV primary infection. J. Clin. Invest.
104, 1431–1439.
Delva, W., and Abdool Karim, Q. (2014). The HIV epidemic in Southern Africa -
Is an AIDS-free generation possible? Curr. HIV/AIDS Rep. 11, 99–108.
Doisne, J.M., Urrutia, A., Lacabaratz-Porret, C., Goujard, C., Meyer, L., Chaix,
M.L., Sinet, M., and Venet, A. (2004). CD8+ T cells specific for EBV, cytomeg-
alovirus, and influenza virus are activated during primary HIV infection.
J. Immunol. 173, 2410–2418.
Fiebig, E.W., Wright, D.J., Rawal, B.D., Garrett, P.E., Schumacher, R.T.,
Peddada, L., Heldebrant, C., Smith, R., Conrad, A., Kleinman, S.H., and
Busch, M.P. (2003). Dynamics of HIV viremia and antibody seroconversion
in plasma donors: implications for diagnosis and staging of primary HIV infec-
tion. AIDS 17, 1871–1879.
Freel, S.A., Lamoreaux, L., Chattopadhyay, P.K., Saunders, K., Zarkowsky, D.,
Overman, R.G., Ochsenbauer, C., Edmonds, T.G., Kappes, J.C., Cunningham,
C.K., et al. (2010). Phenotypic and functional profile of HIV-inhibitory CD8
T cells elicited by natural infection and heterologous prime/boost vaccination.
J. Virol. 84, 4998–5006.ImGerdes, J., Lemke, H., Baisch, H., Wacker, H.H., Schwab, U., and Stein, H.
(1984). Cell cycle analysis of a cell proliferation-associated human nuclear an-
tigen defined by the monoclonal antibody Ki-67. J. Immunol. 133, 1710–1715.
Goonetilleke, N., Liu, M.K., Salazar-Gonzalez, J.F., Ferrari, G., Giorgi, E.,
Ganusov, V.V., Keele, B.F., Learn, G.H., Turnbull, E.L., Salazar, M.G., et al.;
CHAVI Clinical Core B (2009). The first T cell response to transmitted/founder
virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med.
206, 1253–1272.
Grayson, J.M., Zajac, A.J., Altman, J.D., and Ahmed, R. (2000). Cutting edge:
increased expression of Bcl-2 in antigen-specific memory CD8+ T cells.
J. Immunol. 164, 3950–3954.
Hansen, S.G., Ford, J.C., Lewis, M.S., Ventura, A.B., Hughes, C.M., Coyne-
Johnson, L., Whizin, N., Oswald, K., Shoemaker, R., Swanson, T., et al.
(2011). Profound early control of highly pathogenic SIV by an effector memory
T-cell vaccine. Nature 473, 523–527.
Hazenberg, M.D., Stuart, J.W., Otto, S.A., Borleffs, J.C., Boucher, C.A., de
Boer, R.J., Miedema, F., and Hamann, D. (2000). T-cell division in human im-
munodeficiency virus (HIV)-1 infection is mainly due to immune activation: a
longitudinal analysis in patients before and during highly active antiretroviral
therapy (HAART). Blood 95, 249–255.
Hel, Z., Nacsa, J., Tryniszewska, E., Tsai, W.P., Parks, R.W., Montefiori,
D.C., Felber, B.K., Tartaglia, J., Pavlakis, G.N., and Franchini, G. (2002).
Containment of simian immunodeficiency virus infection in vaccinated ma-
caques: correlation with the magnitude of virus-specific pre- and postchal-
lenge CD4+ and CD8+ T cell responses. J. Immunol. 169, 4778–4787.
Huang, J., Ofek, G., Laub, L., Louder, M.K., Doria-Rose, N.A., Longo, N.S.,
Imamichi, H., Bailer, R.T., Chakrabarti, B., Sharma, S.K., et al. (2012). Broad
and potent neutralization of HIV-1 by a gp41-specific human antibody.
Nature 491, 406–412.
Jin, X., Bauer, D.E., Tuttleton, S.E., Lewin, S., Gettie, A., Blanchard, J., Irwin,
C.E., Safrit, J.T., Mittler, J., Weinberger, L., et al. (1999). Dramatic rise in
plasma viremia after CD8(+) T cell depletion in simian immunodeficiency vi-
rus-infected macaques. J. Exp. Med. 189, 991–998.
Kaech, S.M., Tan, J.T., Wherry, E.J., Konieczny, B.T., Surh, C.D., and Ahmed,
R. (2003). Selective expression of the interleukin 7 receptor identifies effector
CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 4, 1191–
1198.
Ka¨gi, D., Vignaux, F., Ledermann, B., Bu¨rki, K., Depraetere, V., Nagata, S.,
Hengartner, H., and Golstein, P. (1994). Fas and perforin pathways as major
mechanisms of T cell-mediated cytotoxicity. Science 265, 528–530.
Kalichman, S.C., Simbayi, L.C., Kagee, A., Toefy, Y., Jooste, S., Cain, D., and
Cherry, C. (2006). Associations of poverty, substance use, and HIV transmis-
sion risk behaviors in three South African communities. Soc. Sci. Med. 62,
1641–1649.
Kiepiela, P., Ngumbela, K., Thobakgale, C., Ramduth, D., Honeyborne, I.,
Moodley, E., Reddy, S., de Pierres, C., Mncube, Z., Mkhwanazi, N., et al.
(2007). CD8+ T-cell responses to different HIV proteins have discordant asso-
ciations with viral load. Nat. Med. 13, 46–53.
Kostense, S., Vandenberghe, K., Joling, J., Van Baarle, D., Nanlohy, N.,
Manting, E., and Miedema, F. (2002). Persistent numbers of tetramer+
CD8(+) T cells, but loss of interferon-gamma+ HIV-specific T cells during pro-
gression to AIDS. Blood 99, 2505–2511.
Koup, R.A., Safrit, J.T., Cao, Y., Andrews, C.A., McLeod, G., Borkowsky, W.,
Farthing, C., and Ho, D.D. (1994). Temporal association of cellular immune re-
sponses with the initial control of viremia in primary human immunodeficiency
virus type 1 syndrome. J. Virol. 68, 4650–4655.
Liu, M.K., Hawkins, N., Ritchie, A.J., Ganusov, V.V., Whale, V., Brackenridge,
S., Li, H., Pavlicek, J.W., Cai, F., Rose-Abrahams, M., et al.; CHAVI Core B
(2013). Vertical T cell immunodominance and epitope entropy determine
HIV-1 escape. J. Clin. Invest. 123, 380–393.
Lyles, R.H., Mun˜oz, A., Yamashita, T.E., Bazmi, H., Detels, R., Rinaldo, C.R.,
Margolick, J.B., Phair, J.P., and Mellors, J.W. (2000). Natural history of human
immunodeficiency virus type 1 viremia after seroconversion and proximal to
AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study.
J. Infect. Dis. 181, 872–880.munity 43, 591–604, September 15, 2015 ª2015 Elsevier Inc. 603
MacPherson, P.A., Fex, C., Sanchez-Dardon, J., Hawley-Foss, N., and Angel,
J.B. (2001). Interleukin-7 receptor expression on CD8(+) T cells is reduced in
HIV infection and partially restored with effective antiretroviral therapy.
J. Acquir. Immune Defic. Syndr. 28, 454–457.
Migueles, S.A., and Connors, M. (2015). Success and failure of the cellular im-
mune response against HIV-1. Nat. Immunol. 16, 563–570.
Migueles, S.A., Laborico, A.C., Shupert, W.L., Sabbaghian, M.S., Rabin, R.,
Hallahan, C.W., Van Baarle, D., Kostense, S., Miedema, F., McLaughlin, M.,
et al. (2002). HIV-specific CD8+ T cell proliferation is coupled to perforin
expression and is maintained in nonprogressors. Nat. Immunol. 3, 1061–1068.
Miller, J.D., van der Most, R.G., Akondy, R.S., Glidewell, J.T., Albott, S.,
Masopust, D., Murali-Krishna, K., Mahar, P.L., Edupuganti, S., Lalor, S.,
et al. (2008). Human effector and memory CD8+ T cell responses to smallpox
and yellow fever vaccines. Immunity 28, 710–722.
Mueller, S.N., Hosiawa-Meagher, K.A., Konieczny, B.T., Sullivan, B.M.,
Bachmann, M.F., Locksley, R.M., Ahmed, R., and Matloubian, M. (2007).
Regulation of homeostatic chemokine expression and cell trafficking during
immune responses. Science, (New York, N.Y 317, 670–674.
Murali-Krishna, K., Altman, J.D., Suresh, M., Sourdive, D.J., Zajac, A.J., Miller,
J.D., Slansky, J., and Ahmed, R. (1998). Counting antigen-specific CD8 T cells:
a reevaluation of bystander activation during viral infection. Immunity 8,
177–187.
Ndhlovu, Z.M., Chibnik, L.B., Proudfoot, J., Vine, S., McMullen, A., Cesa, K.,
Porichis, F., Jones, R.B., Alvino, D.M., Hart, M.G., et al. (2013). High-dimen-
sional immunomonitoring models of HIV-1-specific CD8 T-cell responses
accurately identify subjects achieving spontaneous viral control. Blood 121,
801–811.
Ndung’u, T., Sepako, E., McLane, M.F., Chand, F., Bedi, K., Gaseitsiwe, S.,
Doualla-Bell, F., Peter, T., Thior, I., Moyo, S.M., et al. (2006). HIV-1 subtype
C in vitro growth and coreceptor utilization. Virology 347, 247–260.
Pantaleo, G., Demarest, J.F., Soudeyns, H., Graziosi, C., Denis, F.,
Adelsberger, J.W., Borrow, P., Saag, M.S., Shaw, G.M., Sekaly, R.P., et al.
(1994). Major expansion of CD8+ T cells with a predominant V beta usage dur-
ing the primary immune response to HIV. Nature 370, 463–467.
Phillips, A.N., and Lundgren, J.D. (2006). The CD4 lymphocyte count and risk
of clinical progression. Curr. Opin. HIV AIDS 1, 43–49.
Radebe, M., Nair, K., Chonco, F., Bishop, K., Wright, J.K., van der Stok, M.,
Bassett, I.V., Mncube, Z., Altfeld, M., Walker, B.D., and Ndung’u, T. (2011).
Limited immunogenicity of HIV CD8+ T-cell epitopes in acute Clade C virus
infection. J. Infect. Dis. 204, 768–776.604 Immunity 43, 591–604, September 15, 2015 ª2015 Elsevier Inc.Radebe, M., Gounder, K., Mokgoro, M., Ndhlovu, Z.M., Mncube, Z., Mkhize,
L., van der Stok, M., Jaggernath, M., Walker, B.D., and Ndung’u, T. (2015).
Broad and persistent Gag-specific CD8+ T-cell responses are associated
with viral control but rarely drive viral escape during primary HIV-1 infection.
AIDS 29, 23–33.
Ribeiro, R.M., Qin, L., Chavez, L.L., Li, D., Self, S.G., and Perelson, A.S. (2010).
Estimation of the initial viral growth rate and basic reproductive number during
acute HIV-1 infection. J. Virol. 84, 6096–6102.
Schmitz, J.E., Kuroda, M.J., Santra, S., Sasseville, V.G., Simon, M.A., Lifton,
M.A., Racz, P., Tenner-Racz, K., Dalesandro, M., Scallon, B.J., et al. (1999).
Control of viremia in simian immunodeficiency virus infection byCD8+ lympho-
cytes. Science, (New York, N.Y 283, 857–860.
Streeck, H., Jolin, J.S., Qi, Y., Yassine-Diab, B., Johnson, R.C., Kwon, D.S.,
Addo, M.M., Brumme, C., Routy, J.P., Little, S., et al. (2009). Human immuno-
deficiency virus type 1-specific CD8+ T-cell responses during primary infec-
tion are major determinants of the viral set point and loss of CD4+ T cells.
J. Virol. 83, 7641–7648.
Streeck, H., Lu, R., Beckwith, N., Milazzo, M., Liu, M., Routy, J.P., Little, S.,
Jessen, H., Kelleher, A.D., Hecht, F., et al. (2014). Emergence of individual
HIV-specific CD8 T cell responses during primary HIV-1 infection can deter-
mine long-term disease outcome. J. Virol. 88, 12793–12801.
Trautmann, L., Mbitikon-Kobo, F.M., Goulet, J.P., Peretz, Y., Shi, Y., Van
Grevenynghe, J., Procopio, F.A., Boulassel, M.R., Routy, J.P., Chomont, N.,
et al. (2012). Profound metabolic, functional, and cytolytic differences charac-
terize HIV-specific CD8 T cells in primary and chronic HIV infection. Blood 120,
3466–3477.
Turnbull, E.L., Wong, M., Wang, S., Wei, X., Jones, N.A., Conrod, K.E., Aldam,
D., Turner, J., Pellegrino, P., Keele, B.F., et al. (2009). Kinetics of expansion of
epitope-specific T cell responses during primary HIV-1 infection. J. Immunol.
182, 7131–7145.
Varadarajan, N., Julg, B., Yamanaka, Y.J., Chen, H., Ogunniyi, A.O.,
McAndrew, E., Porter, L.C., Piechocka-Trocha, A., Hill, B.J., Douek, D.C.,
et al. (2011). A high-throughput single-cell analysis of human CD8+ T cell func-
tions reveals discordance for cytokine secretion and cytolysis. J. Clin. Invest.
121, 4322–4331.
Walker, B., and McMichael, A. (2012). The T-cell response to HIV. Cold Spring
Harb. Perspect. Med. 2, a007054.
Wilson, J.D., Ogg, G.S., Allen, R.L., Goulder, P.J., Kelleher, A., Sewell, A.K.,
O’Callaghan, C.A., Rowland-Jones, S.L., Callan, M.F., and McMichael, A.J.
(1998). Oligoclonal expansions of CD8(+) T cells in chronic HIV infection are an-
tigen specific. J. Exp. Med. 188, 785–790.
